OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC

A publication in Nature Reviews Clinical Oncology highlights that datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, has demonstrated an overall survival benefit when used as first-line treatment in patients with advanced-stage triple-negative breast cancer (TNBC). Overall survival is the gold-standard endpoint in oncology trials, and achieving a statistically significant improvement in this aggressive cancer subtype represents a major clinical advance. TNBC accounts for roughly 10–15 percent of all breast cancers and has historically had very limited targeted therapy options, making new effective treatments an urgent unmet need. These results position datopotamab deruxtecan as a potential new standard of care in first-line advanced TNBC, expanding the role of antibody-drug conjugates in breast oncology.